ArticleCancer research2020
Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 19 citations in OpenAlex.
- Spatial Transcriptomics and snRNA-seq Expose CAF Niches Orchestrating Dual Stromal-Immune Barriers in Hepatocellular Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Article
- Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.Cancer communications (London, England) · 2023Review
- Comprehensively prognostic and immunological analysis of snail family transcriptional repressor 2 in pan-cancer and identification in pancreatic carcinoma.Frontiers in immunology · 2023Article
- Heterotypic signaling of cancer-associated fibroblasts in shaping the cancer cell drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2023Review
- Article
- Evolutionary Origins of Metabolic Reprogramming in Cancer.International journal of molecular sciences · 2022Review
- Single-Nucleus RNA Sequencing and Spatial Transcriptomics Reveal the Immunological Microenvironment of Cervical Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- The impact of Angiopoietin-2 genetic polymorphisms on susceptibility for malignant breast neoplasms.Scientific reports · 2022Article
- Article
- M1 Macrophages Enhance Survival and Invasion of Oral Squamous Cell Carcinoma by Inducing GDF15-Mediated ErbB2 Phosphorylation.ACS omega · 2022Article
- Immunoregulation and clinical significance of neutrophils/NETs-ANGPT2 in tumor microenvironment of gastric cancer.Frontiers in immunology · 2022Article
- Article
- Transforming Growth Factor-β: An Agent of Change in the Tumor Microenvironment.Frontiers in cell and developmental biology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 7 institutions in 3 countries.
Adrián Blanco-Gómez *Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.
Lourdes Hontecillas-Prieto *Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.
Roberto Corchado-Cobos *Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.ORCID 0000-0002-3452-2486
Natalia García-Sancha *Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.ORCID 0000-0001-7731-7020
Nélida SalvadorDepartamento de Bioquímica y Biología Molecular; Facultad de Ciencias Químicas y Biológicas, Universidad Complutense, Madrid, Spain.
Andrés Castellanos-MartínInstituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.ORCID 0000-0003-2864-7271
María Del Mar Sáez-FreireInstituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.
Marina Mendiburu-EliçabeInstituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.
Diego Alonso-LópezInstituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.ORCID 0000-0003-1015-9923
Javier De Las RivasInstituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain.
Mar LorenteDepartamento de Bioquímica y Biología Molecular; Facultad de Ciencias Químicas y Biológicas, Universidad Complutense, Madrid, Spain.
Ana García-CasasDepartamento de Bioquímica y Biología Molecular; Facultad de Ciencias Químicas y Biológicas, Universidad Complutense, Madrid, Spain.ORCID 0000-0002-1186-8054
Sofía Del CarmenInstituto de Investigación Biosanitaria de Salamanca (IBSAL), Salamanca, Spain.ORCID 0000-0001-9565-2009
María Del Mar Abad-HernándezInstituto de Investigación Biosanitaria de Salamanca (IBSAL), Salamanca, Spain.
Juan Jesús Cruz-HernándezInstituto de Investigación Biosanitaria de Salamanca (IBSAL), Salamanca, Spain.ORCID 0000-0003-1980-2751
César Augusto Rodríguez-SánchezInstituto de Investigación Biosanitaria de Salamanca (IBSAL), Salamanca, Spain.
Juncal Claros-AmpueroServicio de Oncología, Hospital Universitario de Salamanca, Salamanca, Spain.
Begoña García-CenadorInstituto de Investigación Biosanitaria de Salamanca (IBSAL), Salamanca, Spain.ORCID 0000-0002-8950-8542
Javier García-CriadoInstituto de Investigación Biosanitaria de Salamanca (IBSAL), Salamanca, Spain.ORCID 0000-0003-1724-1233
Akira OrimoDepartment of Pathology and Oncology, Juntendo University School of Medicine, Tokyo, Japan.
Thomas GridleyCenter for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine.
Jesús Pérez-Losada *Instituto de Biología Molecular y Celular del Cáncer (IBMCC-CIC), Universidad de Salamanca/CSIC, Salamanca, Spain. sonica01@ucm.es jperezlosada@usal.es.ORCID 0000-0003-2400-624X
Sonia Castillo-Lluva *Departamento de Bioquímica y Biología Molecular; Facultad de Ciencias Químicas y Biológicas, Universidad Complutense, Madrid, Spain. sonica01@ucm.es jperezlosada@usal.es.ORCID 0000-0001-5357-7178
Instituto de Investigación Biomédica de Salamanca · ESUniversidad Complutense de Madrid · ESUniversidad de Salamanca · ESComplejo Hospitalario de Salamanca · ESCentro de Investigación del Cáncer · ESJuntendo University · JPMaine Medical Center · US
Funding
GENETIC CONTROL OF MESODERM AND NEURAL CREST FORMATIONR01HD034883 · NICHD · MAINEHEALTH · PI GRIDLEY, THOMAS HOOKER · 1998 to 2012
$4.4MNICHD NIH HHS R01 HD034883
Abstract
SNAI2 overexpression appears to be associated with poor prognosis in breast cancer, yet it remains unclear in which breast cancer subtypes this occurs. Here we show that excess SNAI2 is associated with a poor prognosis of luminal B HER2
Indexed as
AnimalsBreast NeoplasmsCancer-Associated FibroblastsCell Line, TumorCell MovementCell ProliferationDisease ProgressionErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHumansMice, KnockoutSnail Family Transcription FactorsStromal CellsTumor MicroenvironmentXenograft Model Antitumor AssaysERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesSNAI2 protein, humanSnai2 protein, mouseSnail Family Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.